JP2020522474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522474A5 JP2020522474A5 JP2019565011A JP2019565011A JP2020522474A5 JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5 JP 2019565011 A JP2019565011 A JP 2019565011A JP 2019565011 A JP2019565011 A JP 2019565011A JP 2020522474 A5 JP2020522474 A5 JP 2020522474A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- variable domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211728A JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510169P | 2017-05-23 | 2017-05-23 | |
| US201762510168P | 2017-05-23 | 2017-05-23 | |
| US201762510137P | 2017-05-23 | 2017-05-23 | |
| US201762510167P | 2017-05-23 | 2017-05-23 | |
| US62/510,168 | 2017-05-23 | ||
| US62/510,169 | 2017-05-23 | ||
| US62/510,137 | 2017-05-23 | ||
| US62/510,167 | 2017-05-23 | ||
| US201762539425P | 2017-07-31 | 2017-07-31 | |
| US62/539,425 | 2017-07-31 | ||
| PCT/US2018/034221 WO2018217945A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Division JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020522474A JP2020522474A (ja) | 2020-07-30 |
| JP2020522474A5 true JP2020522474A5 (enExample) | 2021-07-26 |
Family
ID=64395873
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565011A Pending JP2020522474A (ja) | 2017-05-23 | 2018-05-23 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211728A Pending JP2023030174A (ja) | 2017-05-23 | 2022-12-28 | Ｎｋｇ２ｄ、ｃｄ１６、および腫瘍関連抗原に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157226A1 (enExample) |
| EP (1) | EP3630181A4 (enExample) |
| JP (2) | JP2020522474A (enExample) |
| KR (1) | KR20200010429A (enExample) |
| CN (1) | CN111278460A (enExample) |
| AU (1) | AU2018273250A1 (enExample) |
| BR (1) | BR112019024620A2 (enExample) |
| CA (1) | CA3064567A1 (enExample) |
| IL (1) | IL270801A (enExample) |
| MX (1) | MX2019013995A (enExample) |
| WO (1) | WO2018217945A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US20230287081A1 (en) * | 2020-04-16 | 2023-09-14 | Nantong Yichen Biopharma. Co. Ltd. | PD-1 mutant polypeptide and preparation and application thereof |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2023056252A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| MA71628A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Anticorps anti-gpnmb et leurs méthodes d'utilisation |
| JP2025539937A (ja) | 2022-11-15 | 2025-12-10 | カリコ ライフ サイエンシーズ エルエルシー | 抗ｐａｐｐ－ａ抗体及びその使用方法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20120263722A1 (en) * | 2010-11-04 | 2012-10-18 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| MX348071B (es) * | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| PL2900694T3 (pl) * | 2012-09-27 | 2018-12-31 | Merus N.V. | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| DK3126384T3 (da) * | 2014-04-01 | 2021-01-18 | Adimab Llc | Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse |
| SG10201913680PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| CA2970986C (en) * | 2014-12-19 | 2021-10-26 | Biotecnol Limited | Fusion protein comprising three binding domains to 5t4 and cd3 |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| EP3258967A4 (en) * | 2015-02-20 | 2018-10-03 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| EP3313876B1 (en) * | 2015-06-23 | 2025-01-22 | Innate Pharma | Multispecific antigen binding proteins |
| EP3374389A1 (en) * | 2015-11-13 | 2018-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| US20200048347A1 (en) * | 2016-09-01 | 2020-02-13 | Immunomab, Inc. | Bispecific antibodies |
| DK3579848T3 (da) * | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
-
2018
- 2018-05-23 KR KR1020197037753A patent/KR20200010429A/ko not_active Ceased
- 2018-05-23 EP EP18805878.8A patent/EP3630181A4/en not_active Withdrawn
- 2018-05-23 CN CN201880051761.6A patent/CN111278460A/zh active Pending
- 2018-05-23 BR BR112019024620-7A patent/BR112019024620A2/pt not_active Application Discontinuation
- 2018-05-23 MX MX2019013995A patent/MX2019013995A/es unknown
- 2018-05-23 CA CA3064567A patent/CA3064567A1/en active Pending
- 2018-05-23 US US16/615,231 patent/US20200157226A1/en not_active Abandoned
- 2018-05-23 WO PCT/US2018/034221 patent/WO2018217945A1/en not_active Ceased
- 2018-05-23 AU AU2018273250A patent/AU2018273250A1/en not_active Abandoned
- 2018-05-23 JP JP2019565011A patent/JP2020522474A/ja active Pending
-
2019
- 2019-11-20 IL IL270801A patent/IL270801A/en unknown
-
2022
- 2022-12-28 JP JP2022211728A patent/JP2023030174A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521448A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020508997A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021512630A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| JP2022515318A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2020103301A5 (enExample) | ||
| JP2021523140A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2019536430A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| RU2019128134A (ru) | Антитело против gprc5d и молекула, содержащая антитело | |
| JP2021522162A5 (enExample) | ||
| JP2021523913A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| JP2021510736A5 (enExample) |